alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# Official Journal C 458I/2021

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 458I |
| | |
| English edition | Information and Notices | Volume 6413 November 2021 |

ISSN 1977-091X

Official Journal

of the European Union

C 458I

English edition

Information and Notices

Volume 6413 November 2021

---

| Contents | page |
| --- | --- |
| | IV   Notices |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2021/C 458 I/01 | Summary of European Union decisions on marketing authorisations in respect of medicinal products on 12 November 2021
  (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council) | 1 |

Contents

page

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2021/C 458 I/01

Summary of European Union decisions on marketing authorisations in respect of medicinal products on 12 November 2021
  (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council

1

---

| EN | |
| --- | --- |

EN
# Official Journal C 5/2020

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 5 |
| | |
| English edition | Information and Notices | Volume 639 January 2020 |

ISSN 1977-091X

Official Journal

of the European Union

C 5

English edition

Information and Notices

Volume 639 January 2020

---

| Contents | page |
| --- | --- |
| | II   Information |
| | INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2020/C 5/01 | Non-opposition to a notified concentration (Case M.9583 — TPG/Hong Leong Group/Columbia Asia Healthcare) (
  1
  ) | 1 |

Contents

page

II   Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2020/C 5/01

Non-opposition to a notified concentration (Case M.9583 — TPG/Hong Leong Group/Columbia Asia Healthcare) (
  1
  )

1

1

---

| | IV   Notices |
| --- | --- |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2020/C 5/02 | Euro exchange rates — 8 January 2020 | 2 |

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2020/C 5/02

Euro exchange rates — 8 January 2020

2

---

| | V   Announcements |
| --- | --- |
| | PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY |
| | European Commission |
| 2020/C 5/03 | Prior notification of a concentration (Case M.9688 — Cinven/Astorg/LGC Science Group) Candidate case for simplified procedure (
  1
  ) | 3 |
| 2020/C 5/04 | Prior notification of a concentration (Case M.9668 — JD Sports Fashion/Iberian Sports Retail Group) Candidate case for simplified procedure (
  1
  ) | 5 |
| 2020/C 5/05 | Prior notification of a concentration (Case M.9569 — EssilorLuxottica/GrandVision) (
  1
  ) | 6 |
| | OTHER ACTS |
| | European Commission |
| 2020/C 5/06 | Publication of a communication of approval of a standard amendment to a product specification for a name in the wine sector as referred to in Article 17(2) and (3) of Commission Delegated Regulation (EU) 2019/33 | 7 |

V   Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

2020/C 5/03

Prior notification of a concentration (Case M.9688 — Cinven/Astorg/LGC Science Group) Candidate case for simplified procedure (
  1
  )

1

3

2020/C 5/04

Prior notification of a concentration (Case M.9668 — JD Sports Fashion/Iberian Sports Retail Group) Candidate case for simplified procedure (
  1
  )

1

5

2020/C 5/05

Prior notification of a concentration (Case M.9569 — EssilorLuxottica/GrandVision) (
  1
  )

1

6

OTHER ACTS

European Commission

2020/C 5/06

Publication of a communication of approval of a standard amendment to a product specification for a name in the wine sector as referred to in Article 17(2) and (3) of Commission Delegated Regulation (EU) 2019/33

7

---

| | |
| --- | --- |
| | (1)   Text with EEA relevance. |

---

(1)   Text with EEA relevance.

1

| EN | |
| --- | --- |

EN
Exhibit 31.1

                                 CERTIFICATION



I, Thomas M. Dougherty, certify that:

1.   I have reviewed  this  Amendment No. 2 to the annual report on Form 10-K of
     AirGate PCS, Inc.; and

2.   Based on my knowledge, this report does not contain any untrue statement of
     a material  fact or omit to state a  material  fact  necessary  to make the
     statements made, in light of the circumstances  under which such statements
     were made,  not  misleading  with  respect  to the  period  covered by this
     report.



Date:  January 28, 2004

/s/ Thomas M. Dougherty
--------------------------
Thomas M. Dougherty
Chief Executive Officer
# C_2005281EN.01000101.xml

| 12.11.2005 | EN | Official Journal of the European Union | C 281/1 |
| --- | --- | --- | --- |

12.11.2005

EN

Official Journal of the European Union

C 281/1

---

Election of Presidents of Chambers

(2005/C 281/01)

At a meeting on 6 October 2005, the Judges of the Court of Justice, pursuant to the second subparagraph of Article 10(1) of the Rules of Procedure, elected Sir Konrad Schiemann as President of the Fourth Chamber, Mr Makarczyk as President of the Fifth Chamber and Mr Malenovský as President of the Sixth Chamber, for a period of one year expiring on 6 October 2006.

The composition of the Chambers of the Court of Justice is as follows:

First Chamber

Mr Jann, President,

Sir Konrad Schiemann, Ms Colneric, Mr Cunha Rodrigues, Mr Lenaerts, Mr Juhász, Mr Ilešič and Mr Levits, Judges

Second Chamber

Mr Timmermans, President,

Mr Makarczyk, Mr Gulmann, Mr Schintgen, Ms Silva de Lapuerta, Mr Kūris, Mr Arestis and Mr Klučka, Judges

Third Chamber

Mr Rosas, President,

Mr Malenovský, Mr La Pergola, Mr Puissochet, Mr von Bahr, Mr Borg Barthet, Mr Lõhmus and Mr Ó Caoimh, Judges

Fourth Chamber

Sir Konrad Schiemann, President,

Ms Colneric, Mr Cunha Rodrigues, Mr Lenaerts, Mr Juhász, Mr Ilešič and Mr Levits, Judges

Fifth Chamber

Mr Makarczyk, President,

Mr Gulmann, Mr Schintgen, Ms Silva de Lapuerta, Mr Kūris, Mr Arestis and Mr Klučka, Judges

Sixth Chamber

Mr Malenovský, President,

Mr La Pergola, Mr Puissochet, Mr von Bahr, Mr Borg Barthet, Mr Lõhmus and Mr Ó Caoimh, Judges

---
EX-10.1



 Exhibit 10.1 
 AMENDMENT TO 
 EMPLOYMENT AGREEMENT 

FOR 

RICK M. ROBERTSON 
 This Amendment (the “Amendment”) is entered into this
21st day of July, 2011 (the “Effective Date”),
by and between THE CROGHAN COLONIAL BANK (the “Bank”) and RICK M. ROBERTSON (the “Executive”). 

WHEREAS, the Bank and the Executive entered into an Employment Agreement (the “Agreement”) on November 9, 2010; and

 WHEREAS, pursuant to Section 17 of the Agreement, the Bank, acting through its Board of Directors, and the
Executive may amend the Agreement by a written document executed by both parties; and 
 WHEREAS, in accordance with
Internal Revenue Service Notices 2010-6 and 2010-80, the Bank and the Executive desire to amend the Agreement in certain respects to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended, as they relate
to payment of severance that is conditioned upon the Executive’s provision of a waiver and release of claims; 
 NOW,
THEREFORE, in consideration of the mutual covenants herein contained and other valuable consideration, the receipt and adequacy of which are agreed to by the parties, the Bank and the Executive hereby mutually agree to amend the Agreement by
deleting Section 7 thereof in its entirety and by substituting the following therefore: 
 7. Release.
As a condition to receiving any payments, other than payment of the Accrued Obligations, pursuant to this Agreement, the Executive agrees to release the Bank, Croghan and all of their Affiliates, employees and directors from any and all claims
that the Executive may have against the Bank, Croghan and all of their Affiliates, employees and directors up to and including the date the Executive signs a Waiver and Release of Claims (“Release”) in the form provided by the Bank.
Notwithstanding anything to the contrary in this Agreement, the Executive acknowledges that (a) the Executive is not entitled to receive, and will not receive, any payments pursuant to this Agreement (other than the Accrued Obligations) unless
and until the Executive provides the Bank with said Release and the statutory period during which the Executive is entitled to revoke such Release has expired prior to the time period during which payments are to be made hereunder; and (b) to
the extent that the time period during which payments are to be made to the Executive hereunder begins in one taxable year of the Executive and would end in the subsequent taxable year, any payments to be made to the Executive hereunder will be made
in the second taxable year of the Executive. 







 IN WITNESS WHEREOF, the parties have executed this Amendment on the date first above
written. 
  

					
	BANK	 		 	EXECUTIVE
			
	/s/ James E. Bowlus        	 		 	/s/ Rick M. Robertson        
	Chair, Compensation Committee	 		 	Rick M. Robertson
DISTRICT COURT OF APPEAL OF FLORIDA

SECOND DISTRICT

SUSAN W. DE SAINT PHALLE,

Appellant,

v.

FRANCOIS DE SAINT PHALLE,

Appellee.

No. 2D21-36

September 29, 2021

Appeal pursuant to Fla. R. App. P. 9.130 from the Circuit Court for 

Polk County; James A. Yancey, Judge.

Victor R. Smith and Jeffrey I. Burry of Victor R. Smith Law Group, 

P.A., Winter Haven; John W. Foster of Family Complex Litigation & 

Collaborative Group, Orlando, for Appellant.

Jean Marie Henne of Jean M. Henne, P.A., Winter Haven, for 

Appellee.

PER CURIAM.

Dismissed. Cf. Lliteras v. Lliteras, 413 So. 2d 859 (Fla. 4th 

DCA 1982); Bengisu v. Bengisu, 12 So. 3d 283, 284 (Fla. 4th DCA 
2

2009); Kasm v. Kasm, 933 So. 2d 48, 49–50 (Fla. 2d DCA 2006); 

Jooste v. Jooste, 273 So. 3d 6, 7 (Fla. 4th DCA 2019).

CASANUEVA, LUCAS, and ATKINSON, JJ., Concur.

Opinion subject to revision prior to official publication.
Form of Term Sheet for 2008 Incentive Compensation Plan



 Exhibit 10.2 
 MANTECH INTERNATIONAL CORPORATION 
 Executive Term Sheet 
 For 2008 Incentive Compensation Plan 
 [Date] 
 [Name]: 
 The
Compensation Committee of the Board of Directors (the “Committee”) has determined that you are eligible to participate in the Company’s 2008 Incentive Compensation Plan (the “Plan”). Your participation shall be
subject to the terms and conditions of this Term Sheet and the Plan. A copy of the Plan is attached to this Term Sheet. All capitalized terms in this Term Sheet have the meanings ascribed to them in the Plan. 
 Target Award. The Committee has established a Target Award for you of [xx]% of your base salary. The Target Award is the
amount of incentive compensation that you will earn if 100% of your Participant Goals are achieved.  
 Calculation of Incentive
Compensation. A calculation worksheet is attached to this Term Sheet as Exhibit A. Also included on the calculation worksheet are your Participant Goals and weighting factors, as approved by the Committee. The amount of incentive
compensation you earn, if any, will be determined by converting the Company Performance Score to an Award Percentage using the conversion table included on Exhibit A. The Award Percentage will then be multiplied by your base salary to yield
the incentive compensation payment earned hereunder. 
  

	 	•	 	 If the Company Performance Score does not meet or exceed 90%, then no incentive compensation will be paid hereunder. 


  

	 	•	 	 The maximum total incentive compensation that you can earn hereunder is an amount equal to [xx]% of your base salary. 


  

	 	•	 	 Any incentive compensation payments earned will be paid in accordance with the provisions of the Plan and the Company’s practices, in a lump sum cash payment
after the financial results for 2008 have been finally determined. 


 Unless the Committee, in its discretion, determines
otherwise, your rights to receive the incentive compensation earned hereunder will be forfeited if you are not still an employee of the Company on December 31, 2008. Consistent with the terms of the Plan, the Committee may adjust the incentive
compensation earned hereunder in its discretion if it deems an extraordinary reason exists (in its sole discretion). Notwithstanding anything else herein, no incentive compensation earned hereunder shall be paid until formally approved by the
Committee. The Company will withhold an appropriate amount from such incentive compensation for the payment of all applicable withholding taxes. 
  

			
	ManTech International Corporation
		
	By:	 	  

	Title:	 	  



 Term Sheet for Corporate Executive
exv4w12w10






EXHIBIT 4.12.10




SECOND SENIOR NOTES REGISTRATION RIGHTS JOINDER




     With respect to the registration rights agreement for the 9.875% Senior Notes due 2019,
dated as of August 9, 2011, among RGHL US Escrow II Inc., a company incorporated under the laws of
the State of Delaware (the “US Corporate Escrow Issuer”), RGHL US Escrow II LLC, a limited
liability company organized under the laws of the State of Delaware (the “US LLC Escrow Issuer”
and, together with the US Corporate Escrow Issuer, the “Escrow Issuers”), and Credit Suisse
Securities (USA) LLC, as representative of the Initial Purchasers (as defined therein and, such
agreement, the “Registration Rights Agreement”), for good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the signatory hereto assumes all of the rights and
obligations as a Guarantor under the Registration Rights Agreement, in each case, as of the Escrow
Release Date (as defined in the Registration Rights Agreement) and as though it had entered into
the Registration Rights Agreement on August 9, 2011. The obligations assumed by the signatory
under this joinder shall be joint and several with the obligations of the Guarantors under the
Registration Rights Agreement. Capitalized terms used but not defined in this joinder shall have
the meanings given to such terms in the Registration Rights Agreement.



 









 





     IN WITNESS WHEREOF, the undersigned has executed this joinder to the Registration Rights
Agreement this 8th day of September 2011.



	 	 	 	 	 
	 	GRAHAM PACKAGING COMPANY INC. 

 	 
	 	By:  	/s/ Helen D. Golding
 	 
	 	 	Name:  	Helen D. Golding 	 
	 	 	Title:  	Assistant Secretary 	 
	 



Second Joinder to the Registration Rights Agreement (Senior Notes)
I, Michael W. Kinley, certify that:

1.

I have reviewed this amended annual report on Form 40-F of Cardero Resource Corp.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report;

4.

The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the issuer and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the issuers internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the issuers internal control over financial reporting; and

5.

The issuers other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuers auditors and the audit committee of the issuers board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuers ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the issuers internal control over financial reporting.

Date:  January 30, 2008





/s/ Michael W. Kinley

Michael W. Kinley
Chief Financial Officer
Order entered July 18, 2019

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-19-00807-CV

IN RE SUMMER INFANT (USA), INC., Relator

Original Proceeding from the County Court at Law No. 3

Dallas County, Texas

Trial Court Cause No. CC-14-02235-C

ORDER

Before Justices Bridges, Osborne, and Carlyle

Based on the Court’s opinion of this date, we GRANT relator’s “Motion to Withdraw 

Petition for Writ of Mandamus” and DISMISS this proceeding.

/s/ CORY L. CARLYLE 

JUSTICE
Exhibit 99.1


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Pak Mail Centers of America, Inc.
(the "Company") on Form 10-QSB for the period ending February 28, 2002 as filed
with the Securities and Exchange Commission on the date hereof (the "Report"),
I, P. Evan Lasky, Chief Executive Officer of the Company, certify, pursuant to
18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of
2002, that:

     (1)  The Report fully complies with the requirements of section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and result of operations of
          the Company.



/s/      P. Evan Lasky
--------------------------------
         P. Evan Lasky
         Chief Executive Officer
         January 8, 2003
II 

112TH CONGRESS 

2D SESSION S. 2854 

To extend the temporary suspension of duty on triacetonamine. 

IN THE SENATE OF THE UNITED STATES 

MAY 8, 2012 

Mr. PRYOR introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on 

triacetonamine. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. TRIACETONAMINE. 

4 (a) IN GENERAL.—Heading 9902.25.07 of the Har5 monized Tariff Schedule of the United States (relating to 

6 triacetonamine) is amended by striking the date in the ef7 fective period column and inserting ‘‘12/31/2015’’. 

8 (b) EFFECTIVE DATE.—The amendment made by 

9 subsection (a) applies with respect to goods entered, or 


jbell on DSK7SPTVN1PROD with BILLS
2 

•S 2854 IS

1 withdrawn from warehouse for consumption, on or after 

2 the 15th day after the date of the enactment of this Act. 

Æ 


jbell on DSK7SPTVN1PROD with BILLS
Exhibit 10.12
 
 
 W I T N E S S E T H:
     1.
    
    Access Plans, Inc. shall become a party to the Agreement in substitution for AHC.
 2.
    
    Paragraph 3. (a) Base Salary. shall be amended to reflect a basic annualized
salary of Three Hundred Twenty Five Thousand Dollars ($325,000) effective May 1, 2010.




---



##### 



AHC:Alliance HealthCard, Inc.
    
    AHC-Benefit Marketing Acquisition, Inc.By:
    
    
    
    By:Bradley W. Denison 
Executive Vice President, 
General Counsel and Secretary
    
    Bradley W. Denison 
General CounselDate:
    
    
    
    Date:Access Plans, Inc.By:Bradley W. Denison 
Executive Vice President, 
General Counsel and SecretaryDate:EMPLOYEE:Danny C. WrightDate:
  - 2 -
<PAGE>


                   HMG WORLDWIDE CORPORATION AND SUBSIDIARIES
                                   EXHIBIT 11
                    COMPUTATION OF PER SHARE EARNINGS (LOSS)
                      (IN THOUSANDS, EXCEPT PER SHARE DATA)
                                   (UNAUDITED)


<TABLE>
<CAPTION>
                                                  FOR THE THREE MONTHS ENDED MARCH 31, 2001
                                                    INCOME            SHARES         PER SHARE
                                                   (NUMERATOR)     (DENOMINATOR)        AMOUNT

<S>                                                <C>               <C>             <C>
Basic loss per share                                ($2,584)          15,463          ($0.17)
                                                                                       ======

Effect of dilutive securities:
 Stock options and warrants                              --               --
                                                     ------           ------

Diluted loss per share                              ($2,584)          15,463          ($0.17)
                                                    =======           ======           ======
</TABLE>




<TABLE>
<CAPTION>
                                                  FOR THE THREE MONTHS ENDED MARCH 31, 2000
                                                     INCOME         SHARES         PER SHARE
                                                    (NUMERATOR)  (DENOMINATOR)      AMOUNT


<S>                                                  <C>             <C>             <C>
Basic earnings per share                             $   420         12,308          $0.03
                                                                                     =====

Effect of dilutive securities:
 Stock options and warrants                               --          4,047
                                                     -------         ------

Diluted earnings per share                           $   420         16,355          $0.03
                                                     =======         ======          =====
</TABLE>


                                        1